» Articles » PMID: 34073249

Old and New Challenges in Uveitis Associated with Behçet's Disease

Overview
Journal J Clin Med
Specialty General Medicine
Date 2021 Jun 2
PMID 34073249
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Behçet's disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. The aim of this review is to provide current data on how innovations in clinical evaluation, investigations and treatments were able to improve the prognosis of uveitis associated with BD.

Citing Articles

Immunoregulatory Properties of Immune Cells that Associate with the Lens Capsule Surface during Acute and Resolution Phases of Experimental Autoimmune Uveitis.

Le P, Mattapallil M, Caspi R, Stepp M, Menko A Am J Pathol. 2024; 194(11):2194-2211.

PMID: 39159867 PMC: 11627221. DOI: 10.1016/j.ajpath.2024.07.021.


Behçet's Disease Uveitis.

Joubert M, Desbois A, Domont F, Ghembaza A, Le Joncour A, Mirouse A J Clin Med. 2023; 12(11).

PMID: 37297843 PMC: 10253549. DOI: 10.3390/jcm12113648.


Management of Non-Infectious Uveitis, a Selection of Topical Items Updating.

Seve P, El Jammal T, Gerfaud-Valentin M, Kodjikian L, Jamilloux Y, Jacquot R J Clin Med. 2022; 11(19).

PMID: 36233426 PMC: 9572930. DOI: 10.3390/jcm11195558.

References
1.
. ▼ Daclizumab withdrawn from the market worldwide. Drug Ther Bull. 2018; 56(4):38. DOI: 10.1136/dtb.2018.4.0604. View

2.
Eser Ozturk H, Oray M, Tugal-Tutkun I . Tocilizumab for the Treatment of Behçet Uveitis that Failed Interferon Alpha and Anti-Tumor Necrosis Factor-Alpha Therapy. Ocul Immunol Inflamm. 2017; 26(7):1005-1014. DOI: 10.1080/09273948.2017.1355471. View

3.
Mugheddu C, Atzori L, Del Piano M, Lappi A, Pau M, Murgia S . Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis. Dermatol Ther. 2017; 30(5). DOI: 10.1111/dth.12527. View

4.
Touhami S, Diwo E, Seve P, Trad S, Bielefeld P, Sene D . Expert opinion on the use of biological therapy in non-infectious uveitis. Expert Opin Biol Ther. 2019; 19(5):477-490. DOI: 10.1080/14712598.2019.1595578. View

5.
Cassoux N, Fardeau C, LeHoang P . [Ocular manifestations of Behçet's disease]. Ann Med Interne (Paris). 2000; 150(7):529-34. View